Go to deals
Private Equity | Healthcare

DCN Dx has received a growth equity investment from Martis Capital

DCN Dx, a leading provider of contract development services, has received a growth equity investment from Martis Capital.

DCN Dx offers contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assay. DCN Dx supports an array of customers including global diagnostics manufacturers, nonprofits seeking tests for low-resource settings and start-ups launching diagnostic-based products. Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.

Martis Capital is a private equity firm which manages more than US$1.2 billion of equity and is focused exclusively on investing in middle-market growth companies in the healthcare industry.

One of Oaklins’ teams in the USA, together with Pegasus Capital, served as a financial advisor to DCN Dx, in connection with a growth equity investment from Martis Capital.

Service
M&A sell-side
Parties

Talk to the deal team

 Bradford A. Adams

Bradford A. Adams

Managing Director

Boston, United States
Oaklins TM Capital
 Michael S. Goldman

Michael S. Goldman

Managing Director

New York, United States
Oaklins TM Capital
 James  McLaren

James McLaren

Managing Director

New York, United States
Oaklins TM Capital

Related deals

Permali Gloucester has been acquired by Diamorph (subject to regulatory approval)
Private Equity | Aerospace & Defense | Automotive | Industrial Machinery & Components

Permali Gloucester has been acquired by Diamorph (subject to regulatory approval)

Private equity firm 3i Group and the private shareholders of Permali Gloucester Limited have sold their interest in the company to Diamorph.

Learn more
BaltCap has sold Labochema to French laboratory supply distributor Dominique Dutscher
Private Equity | Other Industries

BaltCap has sold Labochema to French laboratory supply distributor Dominique Dutscher

BaltCap Lithuania SME Fund has sold its 46% shareholding in Labochema UAB, a Lithuanian laboratory supplies trading company, to Dominique Dutscher. Labochema’s CEO and the chairman also sold their shareholdings. As a result of the transaction, Dominique Dutscher now controls 100% of Labochema.

Learn more
Paaschburg & Wunderlich GmbH has been acquired by Bihr N.V.
Private Equity | Consumer & Retail

Paaschburg & Wunderlich GmbH has been acquired by Bihr N.V.

The shareholders of Paaschburg & Wunderlich GmbH (P&W) have sold 100% of their shares to Bihr N.V.

Learn more